Sage Therapeutics (NASDAQ:SAGE) Earns Neutral Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE) in a research note published on Thursday morning, Benzinga reports. The firm currently has a $25.00 target price on the biopharmaceutical company’s stock.

Several other analysts have also commented on SAGE. JPMorgan Chase & Co. lowered Sage Therapeutics from an overweight rating to a neutral rating and decreased their price objective for the company from $18.00 to $12.00 in a report on Thursday. Needham & Company LLC restated a hold rating on shares of Sage Therapeutics in a research note on Wednesday. Scotiabank reduced their target price on Sage Therapeutics from $34.00 to $19.00 and set a sector outperform rating for the company in a research note on Thursday, April 18th. Bank of America lowered Sage Therapeutics from a neutral rating to an underperform rating and reduced their target price for the stock from $24.00 to $14.00 in a research note on Wednesday, April 17th. Finally, Mizuho reduced their target price on Sage Therapeutics from $18.00 to $16.00 and set a neutral rating for the company in a research note on Friday, July 19th. Two analysts have rated the stock with a sell rating, seventeen have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Sage Therapeutics presently has a consensus rating of Hold and a consensus target price of $33.55.

Sage Therapeutics Trading Up 5.0 %

Shares of SAGE opened at $10.99 on Thursday. Sage Therapeutics has a 12 month low of $9.73 and a 12 month high of $37.17. The stock has a fifty day moving average price of $11.28 and a 200-day moving average price of $16.82.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.63) by ($0.17). Sage Therapeutics had a negative net margin of 552.52% and a negative return on equity of 56.81%. The business had revenue of $7.90 million for the quarter, compared to analysts’ expectations of $5.26 million. During the same quarter in the prior year, the company posted ($2.46) EPS. The business’s revenue for the quarter was up 139.4% on a year-over-year basis. As a group, analysts forecast that Sage Therapeutics will post -6.65 earnings per share for the current year.

Hedge Funds Weigh In On Sage Therapeutics

Institutional investors have recently modified their holdings of the stock. Trexquant Investment LP acquired a new stake in shares of Sage Therapeutics during the 4th quarter valued at about $2,234,000. Vanguard Group Inc. boosted its holdings in Sage Therapeutics by 3.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,208,002 shares of the biopharmaceutical company’s stock worth $107,181,000 after buying an additional 175,565 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of Sage Therapeutics by 1,049.2% during the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 201,107 shares of the biopharmaceutical company’s stock worth $4,358,000 after purchasing an additional 183,607 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Sage Therapeutics by 1,058.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 156,593 shares of the biopharmaceutical company’s stock worth $2,935,000 after purchasing an additional 143,075 shares during the last quarter. Finally, abrdn plc acquired a new position in shares of Sage Therapeutics during the 4th quarter worth approximately $1,404,000. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.